nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2016 | original report

ASCO update 2016: colorectal cancer

verfasst von: Wolfgang Eisterer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Summary

At this year’s annual meeting of the American Society of Clinical Oncology, held during 3–7 June 2016 in Chicago, USA, investigators discussed the latest findings in colorectal cancer research. The main topics were immune checkpoint inhibition therapy in colorectal cancer and the prognostic and predictive influence of sidedness in the primary tumor location.

Vorheriger Artikel ASCO update: gastric cancer

Nächster Artikel Extravasation emergencies: state-of-the-art management and progress in clinical research

Venook AP, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil J, Shaw JE, Atkins JN, Horvath LE, Polite BN, Meyerhardt JA, O’Reilly EM, Goldberg RM, Hochster HS, Blanke CD, Schilsky RL, Mayer RJ, Bertagnolli MM, Lenz H‑J. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl):abstr 3504.CrossRef

Venook AP, Niedzwiecki D, Lenz H‑J, Innocenti F, Mahoney MR, O’Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Schilsky RL, Bertagnolli MM, Blanke CD. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(suppl):abstr LBA3.CrossRef

Heinemann V, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S‑E, Heintges T, Lerchenmuller CA, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen CA, Jung A, Kirchner T, Stintzing S. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol. 2014;32(suppl):abstr 3600.CrossRef

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Wong R, Kosmider S, Tran B, Desai T, Hayes TM, Haydon AM, Yip D, Christie M, Strausberg R, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. J Clin Oncol. 2016;34(suppl):abstr 3511.CrossRef

Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz H‑J, Morse MA, Desai J, Hill A, Axelson MD, Moss RA, Lin C‑S, Goldberg M, Andre T. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. J Clin Oncol. 2016;34(suppl):abstr 3501.CrossRef

Bendell JC, Kim TW, Goh BC, Wallin J, Oh D‑Y, Han S‑W, Lee CB, Hellmann MD, Desai J, Lewin JH, Solomon BJ, Chow LQM, Miller WH, Gainor JF, Flaherty K, Infante JR, Das-Thakur M, Foster P, Cha E, Bang Y‑J. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34(suppl):abstr 3502.CrossRef

Le DT, Uram JN, Wang H, Bartlett B, kemberling H, Eyring A, Azad NS, Laheru D, Donehower RC, Crocenzi TS, Goldberg RM, Fisher GA, Lee JJ, Greten TF, Koshiji M, Kang SMP, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 103.CrossRef

Raghav RPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, Muranyi A, Singh S, Routbort M, Chen K, Shaw KR, Shannmugam K, Maru DM, Fakih M, Kopetz S. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(suppl):abstr 3517.CrossRef

Siena S, Sartore-Bianchi A, Lonardi S, Trusolino L, Martino C, Bencardino K, Leone F, Zagonel V, Valtorta E, Torri V, Siravegna G, Amatu A, Bonazzina EF, Rusconi F, Ghezzi S, Ciardiello F, Veronese S, Comoglio PM, Bardelli A, Marsoni S. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol. 2015;33(suppl):abstr 3508.CrossRef

Titel: ASCO update 2016: colorectal cancer
verfasst von: Wolfgang Eisterer
Publikationsdatum: 01.12.2016
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-016-0298-9

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Searching for the Achilles’ heel of cancer

Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation

Primary non-Hodgkin’s lymphoma of the gingiva: a case report and review of the literature

ASCO 2016: highlights in breast cancer

Molecular pathogenesis of chronic myelomonocytic leukemia

Post ASCO update 2016—lung cancer